| Nikolaos Sarantopoulos, DO | |
|
26520 Cactus Ave, Moreno Valley, CA 92555-3927 | |
| (951) 486-4000 | |
| Not Available |
| Full Name | Nikolaos Sarantopoulos |
|---|---|
| Gender | Male |
| Speciality | Student In An Organized Health Care Education/training Program |
| Location | 26520 Cactus Ave, Moreno Valley, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225772833 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 0000 (California) | Secondary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Nikolaos Sarantopoulos, DO 26520 Cactus Ave, Moreno Valley, CA 92555-3927 Ph: (951) 486-4000 | Nikolaos Sarantopoulos, DO 26520 Cactus Ave, Moreno Valley, CA 92555-3927 Ph: (951) 486-4000 |
News Archive
At the 17th annual Sensor + Test Fair this week in Nürnberg, Germany, PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced the debut of an innovative solutions platform for demanding Low Light Level Detection applications, called "L3D."
A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCeptÒ (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens.
Expectant mothers need not be concerned that they are more prone to develop melanoma, or will have a worse prognosis if they do get this serious skin cancer, than women who are not pregnant, according to study results published online as an "article in press" on the Journal of the American College of Surgeons website ahead of print publication.
A team of researchers has demonstrated the clinical efficacy and benefits of a vaccine for a type of blood cancer, follicular lymphoma, amongst first time relapse patients. Specialists from two University of Navarre centres – the University Hospital and the Research Centre for Applied Medicine (CIMA) - have worked jointly since 2001 on the research.
› Verified 9 days ago